Article
Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.
Science (New York, N.Y.) - 3 Jan 2014
Nathanson David A, Gini Beatrice, Mottahedeh Jack, Visnyei Koppany, Koga Tomoyuki, Gomez German, Eskin Ascia, Hwang Kiwook, Wang Jun, Masui Kenta, Paucar Andres, Yang Huijun, Ohashi Minori, Zhu Shaojun, Wykosky Jill, Reed Rachel, Nelson Stanley F, Cloughesy Timothy F, James C David, Rao P Nagesh, Kornblum Harley I, Heath James R, Cavenee Webster K, Furnari Frank B, Mischel Paul S
Abstract excerpt
Intratumoral heterogeneity contributes to cancer drug resistance, but the underlying mechanisms are not understood. Single-cell analyses of patient-derived models and clinical samples from glioblastoma patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) demonstrate that tumor cells reversibly up-regulate or suppress mutant EGFR expression, conferring distinct cellular...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
